# Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Study · id `cardio:ct-nct06926842` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06926842](<https://clinicaltrials.gov/study/NCT06926842>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06926842

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 221 participants.

## Technical summary

Registry record NCT06926842. Randomized; double masking; primary purpose treatment. Start 2025-04-22 (actual); primary completion 2026-08-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 221 participants (enrolled count; ClinicalTrials.gov record NCT06926842, source copy `cardio:ctgov-nct06926842-2026-09-09`, retrieved 2026-10-26)
- Started: 2025-04-22 (actual) (ClinicalTrials.gov record NCT06926842, source copy `cardio:ctgov-nct06926842-2026-09-09`, retrieved 2026-10-26)
- Primary completion: 2026-08-13 (actual) (ClinicalTrials.gov record NCT06926842, source copy `cardio:ctgov-nct06926842-2026-09-09`, retrieved 2026-10-26)
- Completion: 2026-08-13 (actual) (ClinicalTrials.gov record NCT06926842, source copy `cardio:ctgov-nct06926842-2026-09-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06926842, source copy `cardio:ctgov-nct06926842-2026-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06926842-2026-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
- Condition: Overweight
- Condition: Type 2 Diabetes
- Condition: Obesity
- Intervention (Drug): Petrelintide
- Intervention (Other): Placebo
- Lead sponsor: Zealand Pharma
- Lead sponsor class: INDUSTRY
- Collaborator: Parexel
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Parexel (`cardio:org-parexel`)

## Provenance

Content hash: bd4afb087f27c01898001cc54b8d018e848b538b721ac73b74753cfac32731af
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
